Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$255.76B | -61.7x | -1.45 | HK$162.40 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.1% Upside | Upgrade to Pro+ | |
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$202B | 17.1x | -0.88 | HK$73.20 | 3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.3% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$100.29B | 27.3x | 17.91 | HK$26 | 5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$77.34B | -223x | -4.24 | HK$344 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1% Downside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$73.83B | -133.5x | 1.07 | HK$87.25 | 6.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.5% Upside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$48.67B | 133.6x | -1.49 | HK$37.60 | 8.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.6% Upside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$47.41B | 23.1x | 0.77 | HK$16.28 | 5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39% Upside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$36.58B | -71.3x | -0.02 | HK$16.98 | 16.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$32.87B | -16.5x | -1.97 | HK$46.20 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -29% Downside | Upgrade to Pro+ | |
Innocare | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$24.74B | -57.9x | -1.3 | HK$13.16 | 11.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.7% Upside | Upgrade to Pro+ | |
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$18.99B | -30.1x | -0.66 | HK$58.85 | 6.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.2% Upside | Upgrade to Pro+ | |
Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$15.35B | 37.5x | 0.05 | HK$14.80 | 5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -33.1% Downside | Upgrade to Pro+ | |
Keymed Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$13.17B | -22.9x | 0.5 | HK$49.60 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.5% Upside | Upgrade to Pro+ | |
CARsgen Therapeutics Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$10.57B | -9.9x | 1.75 | HK$19.70 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -50.2% Downside | Upgrade to Pro+ | |
TYK Medicines | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$8.79B | -19x | -1.65 | HK$23.55 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26% Upside | Upgrade to Pro+ | |
MiRXES Holding | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$7.79B | -5x | 0.32 | HK$29.15 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alphamab | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$7.67B | 43.3x | 0.27 | HK$8.23 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -45.8% Downside | Upgrade to Pro+ | |
Biocytogen Pharmaceuticals Beijing | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$6.99B | 154.7x | 1.79 | HK$17.96 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -32.5% Downside | Upgrade to Pro+ | |
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$6B | 166.6x | 1.84 | HK$10.38 | 8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.3% Upside | Upgrade to Pro+ | |
ImmuneOnco Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$5.74B | -7x | -0.76 | HK$14.34 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.6% Downside | Upgrade to Pro+ | |
CStone | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$5.31B | -34.5x | -0.72 | HK$4.25 | 8.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.9% Upside | Upgrade to Pro+ | |
Visen Pharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$5.21B | -21.3x | HK$46.55 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Jiangsu Recbio Technology | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.07B | -6.3x | -3.28 | HK$8.52 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jacobio Pharmaceuticals Group | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.03B | -18.2x | -0.48 | HK$5.62 | 10% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -64.2% Downside | Upgrade to Pro+ | |
Qyuns Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.29B | -6.9x | -0.18 | HK$14.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hua Medicine | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.26B | -12x | 0.55 | HK$3.30 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.8% Upside | Upgrade to Pro+ | |
Antengene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.48B | -5.5x | -0.18 | HK$3.94 | 7.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -55% Downside | Upgrade to Pro+ | |
Frontage Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.39B | 370.5x | -4.02 | HK$1.13 | -4.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.4% Downside | Upgrade to Pro+ | |
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2B | -13.9x | -0.38 | HK$0.50 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.63B | -7.8x | -0.17 | HK$3.33 | 5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tot Biopharm Intl | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.51B | 37x | 0.21 | HK$1.93 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | |
HighTide Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.34B | -2.1x | -0.03 | HK$2.69 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genor Biopharma Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.32B | -19.9x | -0.27 | HK$2.72 | 7.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Brii Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.30B | -2.6x | 0.01 | HK$1.89 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -44.2% Downside | Upgrade to Pro+ | |
Sunho Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$828.67M | -6.7x | -0.15 | HK$5.49 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Wuhan YZY Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$819.98M | -8.3x | -0.15 | HK$4.23 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jw Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$737.76M | -1x | -0.05 | HK$2 | 9.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23% Upside | Upgrade to Pro+ | |
Kintor Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$629.59M | -3.6x | -0.04 | HK$1.53 | 5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$388.16M | -0.6x | -0.03 | HK$4.68 | 25.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Clover Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$319.08M | -0.3x | 0 | HK$0.24 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Health Inc | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$155.27M | -14.6x | -0.14 | HK$0.16 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laekna | Hong Kong | Healthcare | Biotechnology & Medical Research | -0.45 | HK$22.15 | 13.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.1% Upside | Upgrade to Pro+ |